Klotho relieves inflammation and exerts a cardioprotective effect during renal ischemia/reperfusion-induced cardiorenal syndrome - 31/08/22
, Marcela Sorelli Carneiro-Ramos a, ⁎, 1 Abstract |
Background |
Renal ischemia and reperfusion injury (IRI) is the main cause of acute kidney injury (AKI). AKI induces the development of cardiac hypertrophy (CH) during cardiorenal syndrome (CRS), and cardiomyocyte calcium mishandling though systemic inflammation after 8 days of renal IRI. Klotho has recently been described as an anti-inflammatory component. Given this, Klotho treatment could prevent or attenuate the inflammation, thereby also preventing electrical cardiac outcomes incurred by CRS. The aim of this study was to investigate the therapeutic role of Klotho in CRS after unilateral renal IRI through its anti-inflammatory action.
Methods |
We examined renal tissue structure and function, intracellular Ca2+ dynamics in adult ventricular cardiomyocytes and serum cytokine levels from C57BL/6 mice that suffered unilateral renal IRI by occluding the left pedicle for 60 min and reperfusion for 8 days. The animals were treated with recombinant Klotho protein starting from the day of the surgery, then daily for 8 days.
Results |
After Klotho treatment for 8 days, the left renal tissue remained damaged, however the renal function was restored due to the right kidney tissue preservation. In parallel, Klotho also prevented an increase in serum interleukin (IL-) 6, IL-1β, and tumor necrosis factor alpha (TNF-α) levels. CH and low cell contraction were also prevented, as well as a decrease in systolic Ca2+ transients and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA2a) activity measured as Ca2+ transient decay, an increase in spontaneous Ca2+ release and the incidence of pro-arrhythmic events.
Conclusions |
The Klotho treatment showed promise, playing an important role in the pathophysiology of CRS. We were unable to observe a total renoprotective role of the compound in the model; in turn, a cardioprotective role of Klotho was demonstrated through the prevention of hypertrophy and normalization of the Ca2+ cycle dysfunction of cardiomyocytes. We propose that Klotho acts in the cardiorenal syndrome by systematically preventing inflammation and increased FGF23, alleviating cardiac outcomes.
Le texte complet de cet article est disponible en PDF.Highlights |
• | AKI induces cardiac hypertrophy and cardiomyocyte calcium mishandling though systemic inflammation . |
• | Klotho prevented an increase in serum interleukin IL- 6, IL-1β, and TNF-α levels as well as FGF23 plasmatic levels. |
• | Klotho plays a cardioprotective role showed by prevention on low cell contraction, a decrease in systolic Ca2+ transients and SERCA activity and the incidence of pro-arrhythmic events. |
• | Klotho treatment showed promise in treatments of cardiac outcomes after primary renal injury. |
Abbreviations : AKI, BNP, CH, CKD, CRS, CVD, EC, FGF23, GFR, HE, HW/BW, HW/TL, IL, IRI, KIM-1, LV, LK, NGAL, RK, RKW, ROS, RyR, SCR, SERCA, SR, TXNIP
Keywords : Cardiorenal syndrome, Cardiomyocyte, Contractile, Acute kidney injury, Renal ischemia and reperfusion
Plan
Vol 153
Article 113515- septembre 2022 Retour au numéro
Article précédent
- Targeted chemo-photodynamic therapy toward esophageal cancer by GSH-sensitive theranostic nanoplatform
- Guodong Ren, ZiCheng Wang, Yafei Tian, Jinyao Li, Yingyu Ma, Liang Zhou, Chengwu Zhang, Lixia Guo, Haipeng Diao, Lihong Li, Li Lu, Sufang Ma, Zhifang Wu, Lili Yan, Wen Liu
- Oridonin attenuates lung inflammation and fibrosis in silicosis via covalent targeting iNOS
- Jingyan Gao, Chao Li, Xialu Wang, Xiaojie Sun, Rong Zhang, Chengcheng chen, Meng Yu, Yongxiang Liu, Yuyan Zhu, Jie Chen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?